Veteran Life Sciences Executive Brings Proven Experience Developing CNS Therapeutics MONTREAL and TORONTO, Jan. 4, 2019 /CNW/ – KalGene Pharmaceuticals Inc., a biotechnology company developing therapeutics to slow the progression of Alzheimer’s disease, today announced the appointment of James Callaway, …
Trending at Lumira Ventures
KalGene Pharmaceuticals And Its Partners Bring an Innovative, Collaborative Approach to Tackle Alzheimer’s Disease
As life expectancies around the globe continue to go up, the accompanying steady rise in senior populations has given way to a newly intensified global focus on dementia in recent years. Dr. Margaret Chan, director-general of the World Health Organization, underscored …
Kalgene Pharmaceuticals: An innovative, collaborative approach to tackle Alzheimer’s disease
IN 2016, AN ESTIMATED 564,000 CANADIANS SUFFERED FROM DEMENTIA. By 2031, says the Alzheimer’s Society of Canada, that figure will rise to 937,000. In the US it is estimated that the Alzheimer’s burden will triple from 5.3 million people today …
KalGene Pharmaceuticals closes financing to support the clinical development of its Alzheimer’s therapeutic
KalGene Pharmaceuticals Inc. today announced the closing of a Series A financing to support the advancement of its lead Alzheimer’s therapeutic program. The syndicated investment was led by Lumira Capital and included participation from Anges Québec, Anges Québec Capital, Accel-Rx …